Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04085601
Recruitment Status : Completed
First Posted : September 11, 2019
Last Update Posted : December 1, 2021
Information provided by (Responsible Party):
Apellis Pharmaceuticals, Inc.

Brief Summary:
Evaluation of the Efficacy and Safety of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria .

Condition or disease Intervention/treatment Phase
Paroxysmal Nocturnal Hemoglobinuria Drug: APL-2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 53 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Multicenter, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Actual Study Start Date : August 15, 2019
Actual Primary Completion Date : June 23, 2021
Actual Study Completion Date : June 23, 2021

Arm Intervention/treatment
No Intervention: Standard of Care (SOC) excluding complement inhibitors
Experimental: 1,080mg APL-2 administered subcutaneously twice weekly Drug: APL-2
Complement (C3) Inhibitor

Primary Outcome Measures :
  1. Hemoglobin stabilization defined as avoidance of a > 1 g/dl decrease in hemoglobin levels in the absence of transfusion. [ Time Frame: Baseline through Week 26 ]
  2. Reduction in lactate dehydrogenase (LDH) level [ Time Frame: Baseline to Week 26 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Be at least 18 years old (inclusive).
  • Have LDH ≥1.5 x ULN at the screening visit.
  • Have PNH diagnosis, confirmed by high sensitivity flow cytometry (granulocyte or monocyte clone >10%).
  • Have Hb less than the lower limit of normal (LLN) at the screening visit.
  • Have ferritin greater than/equal to the LLN, or total iron binding capacity (TIBC) less than/equal to ULN at the screening visit, based on central laboratory reference ranges. If a subject is receiving iron supplements at screening, the Investigator must ensure that the subject's dose has been stable for 4 weeks prior to screening, and it must be maintained throughout the study. Subjects not receiving iron at screening must not start iron supplementation during the course of the study.
  • Body mass index (BMI) ≤ 35 kg/m2 at the screening visit.
  • Have a platelet count of >50,000/mm3 at the screening visit.
  • Have an absolute neutrophil count >500/mm3 at the screening visit.

Exclusion Criteria:

  • Treatment with any complement inhibitor (eg, eculizumab) within 3 months prior to screening.
  • Hereditary complement deficiency.
  • History of bone marrow transplantation.
  • Concomitant use of any of the following medications is prohibited if not on a stable regimen for the time period indicated below prior to screening:

    • Erythropoietin or immunosuppressants for at least 8 weeks
    • Systemic corticosteroids for at least 4 weeks
    • Vitamin K antagonists (eg, warfarin) with a stable international normalized ratio (INR) for at least 4 weeks
    • Iron supplements, vitamin B12, or folic acid for at least 4 weeks
    • Low-molecular-weight heparin for at least 4 weeks

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04085601

Show Show 30 study locations
Sponsors and Collaborators
Apellis Pharmaceuticals, Inc.
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Apellis Pharmaceuticals, Inc. Identifier: NCT04085601    
Other Study ID Numbers: APL2-308
First Posted: September 11, 2019    Key Record Dates
Last Update Posted: December 1, 2021
Last Verified: November 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemoglobinuria, Paroxysmal
Urination Disorders
Urologic Diseases
Urological Manifestations
Anemia, Hemolytic
Hematologic Diseases
Myelodysplastic Syndromes
Bone Marrow Diseases